ATOPIC DERMATITIS (AD)

This study checked the safety and how well the drug upadacitinib works in over 2300 Korean patients with rheumatoid arthritis, atopic dermatitis, ankylosing spondylitis, or psoriatic arthritis. Patients took the drug as prescribed by their doctor and were followed for about 28 we…

This study tested a cream called Revodiol Calming Cream on 42 children and adults with mild to moderate eczema (atopic dermatitis). Participants applied the cream twice daily for 56 days. Researchers measured improvements in skin hydration, redness, dryness, and itching using ski…

This study tested a cream called roflumilast (ZORYVE®) in 354 people aged 6 and older with mild to moderate eczema. Participants applied the cream once daily for 4 weeks. The goal was to see if the cream could clear or nearly clear the skin rash better than a cream with no active…

This early-stage study tested a new drug called ENV-294 in 9 adults with moderate-to-severe atopic dermatitis (eczema). The main goal was to check if the drug is safe and tolerable when taken daily for 28 days. Researchers also looked for any changes in skin symptoms. This is a s…

This study tested whether a cream containing N-acetyl cysteine (NAC) helps people with mild to moderate eczema. The goal was to reduce harmful bacteria on the skin and improve eczema symptoms. One hundred adults took part, applying either the NAC cream or a plain moisturizer. The…

This study tested a new ointment called CGB-500 (tofacitinib) for treating atopic dermatitis, a common skin condition. Three people aged 12 and older applied the ointment and a comparator twice daily for four weeks. The goal was to see if it reduces skin redness and itching safel…

This study tested an experimental ointment called MH004 in 160 healthy adults and people with mild to moderate atopic dermatitis (eczema). The goal was to see if the ointment is safe and can reduce eczema severity. Researchers measured skin improvement and side effects over sever…

This study tested whether an ointment containing tofacitinib (CGB-500) can safely reduce eczema symptoms. 180 people ages 12 and older applied the ointment or a placebo daily for 8 weeks. Researchers tracked skin clearing and side effects to see if the treatment works.

This study tested an experimental drug, EVO301, in 71 adults with moderate-to-severe atopic dermatitis (eczema). The goal was to see if the drug safely reduces skin redness, thickness, and itch. Participants received either EVO301 or a placebo, and doctors measured changes in ski…

This study tested an ointment called MH004 in 375 people aged 12 and older with mild to moderate eczema (atopic dermatitis). The goal was to see if it safely clears or nearly clears skin within 4 to 8 weeks. Participants applied the ointment or a placebo cream, and those who join…

This study tested a special SPF50+ sunscreen on 22 children with mild-to-moderate atopic dermatitis (eczema) to see if it would irritate their skin. Doctors checked how well the children's skin tolerated the sunscreen. The goal was to find a safe sun protection option for kids wi…

This early-phase study tested a new medicine called VC005 in 11 teenagers aged 12 to 18 with mild to moderate atopic dermatitis (eczema). The main goals were to check safety and how the drug moves through the body. Researchers measured drug levels in the blood over time. This is …

This study tested a strong SPF50+ sunscreen on 42 adults with mild to moderate atopic dermatitis (eczema). Over 22 days, doctors checked how well the skin tolerated the product and how satisfied users were. The goal was to see if the sunscreen is both gentle and effective for sen…

This study tested an experimental drug called LW402 in 144 adults with moderate-to-severe atopic dermatitis (eczema). The goal was to see if the drug reduces eczema severity, measured by a 50% improvement in skin symptoms after 12 weeks. Participants were randomly assigned to rec…

This study tracked 581 pregnant women to see if the drug dupilumab (used for eczema or asthma) affects pregnancy or baby health. It compared women who took dupilumab to those with the same diseases who did not, and to healthy pregnant women. The goal was to check for birth defect…